The world’s leading cannabis and psychedelic medicines scientists and researchers, investors, industry leaders and opinion makers will gather in Tel Aviv next month for two conferences focussing on next-level plant-based medicine.
The conferences will be looking at cannabis and psychedelics as medicines. Celebrating its 5th year, the iconic CannaTech Tel Aviv Conference will take place March 30-31, 2020, and PsyTech will become a discovery platform to incubate psychedelic medicine.
CannaTech is an Israeli-founded global cannabis event widely recognised as the industry’s premier experience for education, networking and access to global cannabis dealflow.
Over 1,200 participants from more than 40 countries will attend CannaTech Tel Aviv to learn from more than 50 expert speakers about the latest scientific and business developments in the field focussing on research, markets and finance, agricultural innovation, and regulatory and government policy.
According to a recent Prohibition Partners report, worldwide legal cannabis revenue will increase to $103.9bn by 2024 as demand surges globally for cannabis-derived medicine, and more countries and US states legalise use of the plant for both medical and recreational use.
Saul Kaye, Founder and CEO of CannaTech and iCAN Israel-Cannabis, said: “I started CannaTech 5 years ago as a small industry event in Tel Aviv and it’s evolved into a global platform. We continue to make strides in breaking the stigma around medical cannabis.
“We’re seeing governments worldwide institute legalisation programmes. Israel remains at the forefront of a still nascent global medical industry and together, with partners from around the world, we will help millions of patients in need. I could not be prouder to showcase the advances we have made, here, in beautiful Tel Aviv.”
Created by the team behind CannaTech, the PsyTech Summit is Israel’s first conference to focus on innovation and investment in psychedelic medicine. PsyTech will take place on March 29-31, 2020.
With renewed research interest in MDMA, ketamine and psilocybin (or “magic mushrooms“), and a growing normalisation after decades of stigma, cannabis and psychedelics as medicines are quickly becoming the next therapeutic frontier.
Israel has emerged as a leader in using psychedelics to treat Post Traumatic Stress Disorder (PTSD) and treatment-resistant depression. PsyTech is building the global psychedelic ecosystem to elevate psychedelic medicine, foster normalisation, and accelerate innovation and dealflow.
PsyTech’s audience are medical and scientific professionals as well as investors who see the immense industry potential in new treatments for various mental health indications.
Growing evidence points to the potential of psychedelics in the treatment of mental health problems and symptoms, including depression and anxiety, obsessive-compulsive disorder, and, opioid, alcohol and tobacco addiction. Clinical trials on psychedelic therapies are now underway in universities including Yale and John Hopkins, and Imperial College London and in leading hospitals throughout Israel.
Currently, Israel’s Ministry of Health has approved using MDMA, popularly known as “Ecstasy” to treat fifty patients suffering from PTSD in four Israeli hospitals. Israel is the only country in the world where the government is funding studies using psilocybin for treatment resistant depression.
Psilocybin received “Breakthrough Therapy” designation from the US Food and Drug Administration (FDA) in 2018 after evidence showed it may be more beneficial than current treatments for major depressive disorder (MDD). The non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) was also granted application for an Expanded Access Program for MDMA-assisted psychotherapy for PTSD by the FDA.
“Psychedelics are the next therapeutic frontier with great promise and a different approach to therapy and wellness that is yielding amazing scientifically-validated results,” said Hayim Raclaw, Managing Director of PsyTech.
“PsyTech will see the biggest names in the industry come together in Tel Aviv, the heart of the Start-Up Nation, to propel the global psychedelic medication conversation. We believe the sector is about to explode as a wave of new information, research and consumer interest about psychedelics floods the market.”
International experts speaking at PsyTech include Christian Angermayer, Founder of ATAI Life Sciences, Rick Doblin, Ph.D., Executive Director of Multidisciplinary Association for Psychedelic Studies (MAPS), Bruce Linton, Founder and Former Chairman and Co-CEO of Canopy Growth Corporation, Dr Rosalind Watts, Clinical Psychologist at the Psychedelic Research Group at Imperial College London, and JR Rahn, Founder & Co-CEO of MindMed.
The overlapping events will allow interested participants to explore the distinct fields and discover synergies that may be helpful in moving forward.
CannaTech’s Kaye, said: “With ever-growing patient, government and corporate acceptance of cannabis as medicine the road has been paved for psychedelics to enter mainstream medical use. The emerging psychedelics industry has much to learn from the medical cannabis experience.”